Analysts Expect HCA Holdings, Inc. (HCA) to Announce $1.87 EPS
Analysts forecast that HCA Holdings, Inc. (NYSE:HCA) will report $1.87 earnings per share for the current quarter, according to Zacks. Ten analysts have issued estimates for HCA’s earnings. The highest EPS estimate is $1.95 and the lowest is $1.80. HCA posted earnings per share of $1.89 in the same quarter last year, which suggests a negative year-over-year growth rate of 1.1%. The business is expected to issue its next quarterly earnings report on Tuesday, January 30th.
On average, analysts expect that HCA will report full year earnings of $6.56 per share for the current financial year, with EPS estimates ranging from $6.49 to $6.64. For the next year, analysts expect that the firm will post earnings of $7.19 per share, with EPS estimates ranging from $6.58 to $7.60. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for HCA.
HCA (NYSE:HCA) last announced its earnings results on Tuesday, October 31st. The company reported $1.21 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.21. The company had revenue of $10.70 billion for the quarter, compared to analyst estimates of $10.70 billion. HCA had a negative return on equity of 47.16% and a net margin of 6.13%. HCA’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.45 earnings per share.
A number of research analysts have recently weighed in on HCA shares. Robert W. Baird reiterated a “buy” rating on shares of HCA in a report on Thursday, September 28th. Credit Suisse Group started coverage on HCA in a report on Thursday, November 2nd. They set an “outperform” rating and a $95.00 price target on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $95.00 price target on shares of HCA in a report on Friday, October 13th. Piper Jaffray Companies reiterated a “buy” rating and set a $92.00 price target on shares of HCA in a report on Wednesday, October 4th. Finally, Raymond James Financial downgraded HCA from a “strong-buy” rating to a “market perform” rating in a report on Wednesday, October 18th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $90.20.
In other HCA news, insider Michael S. Cuffe sold 2,150 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $78.00, for a total value of $167,700.00. Following the transaction, the insider now owns 12,476 shares in the company, valued at $973,128. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Victor L. Campbell sold 8,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $75.82, for a total value of $606,560.00. Following the completion of the transaction, the senior vice president now owns 127,275 shares in the company, valued at approximately $9,649,990.50. The disclosure for this sale can be found here. Insiders sold 20,300 shares of company stock worth $1,565,960 in the last 90 days. Corporate insiders own 2.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of HCA. Strs Ohio lifted its position in shares of HCA by 12.2% in the third quarter. Strs Ohio now owns 1,075,778 shares of the company’s stock worth $85,621,000 after buying an additional 117,000 shares during the last quarter. Micawber Capital LLC lifted its position in shares of HCA by 31.3% in the third quarter. Micawber Capital LLC now owns 34,461 shares of the company’s stock worth $2,743,000 after buying an additional 8,205 shares during the last quarter. Toronto Dominion Bank lifted its position in shares of HCA by 12.8% in the third quarter. Toronto Dominion Bank now owns 112,657 shares of the company’s stock worth $8,965,000 after buying an additional 12,744 shares during the last quarter. American Century Companies Inc. lifted its position in shares of HCA by 49.5% in the third quarter. American Century Companies Inc. now owns 2,558,216 shares of the company’s stock worth $203,608,000 after buying an additional 847,377 shares during the last quarter. Finally, Accident Compensation Corp lifted its position in shares of HCA by 4.8% in the second quarter. Accident Compensation Corp now owns 43,793 shares of the company’s stock worth $3,819,000 after buying an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 75.35% of the company’s stock.
Shares of HCA (HCA) traded up $2.31 during trading on Tuesday, hitting $88.46. The stock had a trading volume of 3,752,218 shares, compared to its average volume of 2,302,826. HCA has a 12 month low of $71.18 and a 12 month high of $91.03. The company has a quick ratio of 1.41, a current ratio of 1.68 and a debt-to-equity ratio of -6.46. The firm has a market capitalization of $31,960.00, a price-to-earnings ratio of 13.29, a PEG ratio of 1.29 and a beta of 0.55.
HCA Company Profile
HCA Healthcare, Inc, formerly HCA Holdings, Inc, is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HCA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA and related companies with Analyst Ratings Network's FREE daily email newsletter.